Feasibility trial of adjuvant chemotherapy with docetaxel (DOC) plus cisplatin (CDDP) followed by maintenance chemotherapy of S-1 in completely resected non-small cell lung cancer (NSCLC): Thoracic Oncology Research Group (TORG) 0809.
Seiji Niho
Honoraria - Lilly; Sanofi ; Taiho Pharmaceutical
Kenji Suzuki
Honoraria - Taiho Pharmaceutical
Hiroshi Sakai
Honoraria - Chugai Pharma; Lilly; Sanofi ; Taiho Pharmaceutical
Takayuki Kaburagi
No relevant relationships to disclose
Teruaki Koike
No relevant relationships to disclose
Koichi Minato
No relevant relationships to disclose
Terufumi Kato
Honoraria - Sanofi ; Taiho Pharmaceutical
Hiroaki Okamoto
Honoraria - Chugai Pharma; Janssen Pharmaceutical ; Kyowa Hakko Kirin; Lilly; Sanofi ; Taiho Pharmaceutical
Takashi Seto
Honoraria - Sanofi ; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Yukio Hosomi
No relevant relationships to disclose
Kimihiro Shimizu
No relevant relationships to disclose
Fumihiro Oshita
No relevant relationships to disclose
Masanori Tsuchida
No relevant relationships to disclose
Motohiro Yamashita
No relevant relationships to disclose
Osamu Kawashima
No relevant relationships to disclose
Kazuma Kishi
Honoraria - Sanofi ; Taiho Pharmaceutical
Research Funding - Taiho Pharmaceutical
Hideo Kunitoh
Honoraria - Sanofi ; Taiho Pharmaceutical
Masahiro Takeuchi
No relevant relationships to disclose
Koshiro Watanabe
No relevant relationships to disclose
Norihiko Ikeda
Honoraria - Sanofi ; Taiho Pharmaceutical
Research Funding - Sanofi ; Taiho Pharmaceutical